sb 203580 has been researched along with lentinan in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (lentinan) | Trials (lentinan) | Recent Studies (post-2010) (lentinan) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 495 | 36 | 152 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dai, S; Dong, L; Li, H; Liu, Q; Peng, Y; Yuan, J | 1 |
1 other study(ies) available for sb 203580 and lentinan
Article | Year |
---|---|
Lentinan mitigates therarubicin-induced myelosuppression by activating bone marrow-derived macrophages in an MAPK/NF-κB-dependent manner.
Topics: Animals; Anthracenes; Bone Marrow; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; I-kappa B Proteins; Imidazoles; Lentinan; Leukocytes; Macrophages; Male; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinases; Neutrophils; NF-kappa B; Pyridines | 2016 |